Insider Selling: Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells 3,415 Shares of Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Heather Ann Mcsharry sold 3,415 shares of the company’s stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $177.78, for a total value of $607,118.70. Following the sale, the director owned 20,449 shares in the company, valued at $3,635,423.22. The trade was a 14.31% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Jazz Pharmaceuticals Stock Up 2.2%

JAZZ stock traded up $3.97 during mid-day trading on Monday, reaching $180.90. The company had a trading volume of 2,027,413 shares, compared to its average volume of 952,323. The company has a market capitalization of $10.99 billion, a price-to-earnings ratio of -26.88, a PEG ratio of 8.49 and a beta of 0.29. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $182.99. The stock has a 50 day simple moving average of $138.86 and a two-hundred day simple moving average of $122.58. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Wednesday, November 5th. The specialty pharmaceutical company reported $8.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.87 by $2.26. The company had revenue of $1.13 billion for the quarter, compared to analysts’ expectations of $1.11 billion. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The business’s revenue was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $6.54 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 7.650-8.450 EPS. As a group, equities analysts predict that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Jazz Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. Hurley Capital LLC bought a new stake in Jazz Pharmaceuticals in the 1st quarter valued at $25,000. Picton Mahoney Asset Management lifted its holdings in shares of Jazz Pharmaceuticals by 2,445.5% during the first quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company’s stock worth $34,000 after buying an additional 269 shares in the last quarter. Farther Finance Advisors LLC boosted its position in shares of Jazz Pharmaceuticals by 754.8% in the third quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock valued at $35,000 after acquiring an additional 234 shares during the period. SVB Wealth LLC acquired a new position in shares of Jazz Pharmaceuticals in the first quarter valued at about $36,000. Finally, Hantz Financial Services Inc. grew its stake in shares of Jazz Pharmaceuticals by 471.4% in the second quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock valued at $38,000 after acquiring an additional 297 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Needham & Company LLC reissued a “buy” rating and issued a $202.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, August 28th. Morgan Stanley raised their target price on shares of Jazz Pharmaceuticals from $185.00 to $205.00 and gave the company an “overweight” rating in a research note on Monday, November 17th. Zacks Research upgraded Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Friday, August 15th. Wall Street Zen raised Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Finally, Robert W. Baird raised their price objective on Jazz Pharmaceuticals from $160.00 to $209.00 and gave the company an “outperform” rating in a research report on Tuesday, November 18th. Thirteen investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $195.67.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.